Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22969785 | 0.98 | LMNA (0.33) | LMNAKMT2A | |
| SCHEMBL24730511 | 0.89 | — | — | |
| SCHEMBL2455158 | 0.78 | LMNA (0.39) | LMNAKMT2ATHRBTP53OPRM1 | |
| SCHEMBL24359198 | 0.75 | — | — | |
| SCHEMBL24359206 | 0.75 | CYP2D6 (0.35) | — | |
| SCHEMBL24730836 | 0.74 | — | — | |
| SCHEMBL29343837 | 0.73 | — | — | |
| SCHEMBL22970030 | 0.73 | LMNA (0.35) | LMNAKMT2ATHRBTP53OPRM1 | |
| SCHEMBL14486972 | 0.73 | — | — | |
| SCHEMBL22967780 | 0.72 | SLC6A3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040089-A1 | KRAS MUTANT PROTEIN INHIBITORS | KRAS, NRAS, APC | LMNA 3937/4885KMT2A 3115/4885THRB 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.